- Home
- URGN vs UFCS Comparison
URGN vs UFCS Comparison
Compare URGN & UFCS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- URGN
- UFCS
- Stock Information
- Founded
- URGN 2004
- UFCS 1946
- Country
- URGN United States
- UFCS United States
- Employees
- URGN N/A
- UFCS 877
- Industry
- URGN Biotechnology: Pharmaceutical Preparations
- UFCS Property-Casualty Insurers
- Sector
- URGN Health Care
- UFCS Finance
- Exchange
- URGN Nasdaq
- UFCS Nasdaq
- Market Cap
- URGN 904.0M
- UFCS 791.8M
- IPO Year
- URGN 2017
- UFCS N/A
- Fundamental
- Price
- URGN $18.94
- UFCS $31.73
- Analyst Decision
- URGN Strong Buy
- UFCS Buy
- Analyst Count
- URGN 8
- UFCS 2
- Target Price
- URGN $28.50
- UFCS $30.50
- AVG Volume (30 Days)
- URGN 1.1M
- UFCS 118.3K
- Earning Date
- URGN 11-05-2025
- UFCS 11-04-2025
- Dividend Yield
- URGN N/A
- UFCS 2.01%
- EPS Growth
- URGN N/A
- UFCS 143.32
- EPS
- URGN N/A
- UFCS 3.51
- Revenue
- URGN $94,238,000.00
- UFCS $1,322,727,000.00
- Revenue This Year
- URGN $35.60
- UFCS $12.34
- Revenue Next Year
- URGN $129.54
- UFCS $14.56
- P/E Ratio
- URGN N/A
- UFCS $9.10
- Revenue Growth
- URGN 10.85
- UFCS 14.18
- 52 Week Low
- URGN $3.42
- UFCS $19.19
- 52 Week High
- URGN $21.71
- UFCS $32.13
- Technical
- Relative Strength Index (RSI)
- URGN 49.18
- UFCS 60.64
- Support Level
- URGN $18.45
- UFCS $30.53
- Resistance Level
- URGN $21.71
- UFCS $31.97
- Average True Range (ATR)
- URGN 1.18
- UFCS 0.67
- MACD
- URGN -0.17
- UFCS -0.04
- Stochastic Oscillator
- URGN 20.90
- UFCS 71.34
About URGN UroGen Pharma Ltd.
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. Their flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with investigational candidate UGN-102 (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. Additionally, their immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, intended for both monotherapy and combination therapy. Revenue is generated from product sales.
About UFCS United Fire Group Inc.
United Fire Group Inc is engaged in the business of writing property and casualty insurance and selling annuities through a network of independent agencies. The company's only operating segment is property and casualty insurance, which includes commercial lines insurance, personal lines insurance, and assumed reinsurance. The primary source of revenue is premium and investment income.